Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $2.7 million.

  • Monte Rosa Therapeutics' Non Operating Income fell 80.32% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 3478.04%. This contributed to the annual value of $11.0 million for FY2024, which is 3236.11% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Non Operating Income of $2.7 million as of Q3 2025, which was down 80.32% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Non Operating Income peaked at $4.5 million during Q2 2025, and registered a low of $1.6 million during Q4 2023.
  • Its 3-year average for Non Operating Income is $2.7 million, with a median of $2.6 million in 2024.
  • Over the last 5 years, Monte Rosa Therapeutics' Non Operating Income had its largest YoY gain of 7252.32% in 2025, and its largest YoY loss of 80.32% in 2025.
  • Monte Rosa Therapeutics' Non Operating Income (Quarter) stood at $1.6 million in 2023, then soared by 63.44% to $2.6 million in 2024, then rose by 4.62% to $2.7 million in 2025.
  • Its Non Operating Income was $2.7 million in Q3 2025, compared to $4.5 million in Q2 2025 and $3.7 million in Q1 2025.